Icon

ZYPREXA (nda020592)- (2.5MG,5MG,7.5MG,10MG,15MG,20MG)

OLANZAPINE CHEPLAPHARM
2.5MG,5MG,7.5MG,10MG,15MG,20MG
Yes No
2018-Mar-23 Expired
None None
None No
ZYPREXA® (olanzapine) is an atypical antipsychotic indicated: As oral formulation for the: • Treatment of schizophrenia. • Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. • Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. • Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder.
13 1 10
Total Other Developers 4
Drugs with Suitability No
2.5MG ** ** - - 5
5MG ** ** - 4 1
7.5MG ** ** - 4 1
10MG ** ** Up 4 1
15MG ** ** Up - 5
20MG ** ** Up 4 1
NDA Sales Available Total Generic Sales Available
Yes 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ****** *** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ********* ****** *** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** ******** ****** ******* ******* *** *********** ****-**, ****** **. ** & **, ************* ******* ***- *********, ******** ******, **********, ********* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** **** **** ************** **., ***.(**** **** **** ****) *********** **.***, ****** ****, ****-**** ****, *****, ******, ***** (***) ***
****** **** **** ************** **., ***. (********** ********** ****) *********** **** ***** ****, ****-**** ****, *****, ******, ***** (***) ***
****** ****** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****,, ***, *** ******, ***** (***) ***
****** ****** ****** *** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.